Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Rae

Showing results (261-270 of 292) with videos related to

Pageof 30
Sort By:
NPJ Breast Cancer|March 11, 2022
Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer modelsAnna R Michmerhuizen, Lynn M Lerner, Andrea M Pesch, et al.
NPJ Breast Cancer|April 21, 2022
Publisher Correction: Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer modelsAnna R Michmerhuizen, Lynn M Lerner, Andrea M Pesch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 21, 2010
Gene polymorphisms in cyclophosphamide metabolism pathway,treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancerSong Yao, William E Barlow, Kathy S Albain, et al.
Journal of the National Cancer Institute|March 8, 2012
CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trialMeredith M Regan, Brian Leyland-Jones, Mark Bouzyk, et al.
Genes & Development|May 29, 2025
NOTCH1 S2513 is critical for the regulation of NICD levels impacting the segmentation clock in hiPSC-derived PSM cells and somitoidsHedda A Meijer, Adam Hetherington, Sara J Johnson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2009
Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trialJi-Yeob Choi, William E Barlow, Kathy S Albain, et al.
Journal of Medicinal Chemistry|April 8, 2025
Correction to "Discovery of ERD-1233 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader for the Treatment of ER+ Human Breast Cancer"Ranjan Kumar Acharyya, Rohan Kalyan Rej, Biao Hu, et al.
Breast Cancer Research and Treatment|March 24, 2010
Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancerSong Yao, William E Barlow, Kathy S Albain, et al.
Journal of Medicinal Chemistry|November 1, 2024
Discovery of ERD-1233 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader for the Treatment of ER+ Human Breast CancerRanjan Kumar Acharyya, Rohan Kalyan Rej, Biao Hu, et al.
Pharmacogenomics|August 24, 2023
Effects of <i>CYP3A4</i> and <i>CYP2C9</i> genotype on systemic anastrozole and fulvestrant concentrations in SWOG S0226Delaney V Rutherford, Sarah Medley, Nicholas C Henderson, et al.
Pageof 30

Showing results (261-270 of 292) with videos related to

Sort By:
Pageof 30
NPJ Breast Cancer|March 11, 2022
Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer modelsAnna R Michmerhuizen, Lynn M Lerner, Andrea M Pesch, et al.
NPJ Breast Cancer|April 21, 2022
Publisher Correction: Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer modelsAnna R Michmerhuizen, Lynn M Lerner, Andrea M Pesch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 21, 2010
Gene polymorphisms in cyclophosphamide metabolism pathway,treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancerSong Yao, William E Barlow, Kathy S Albain, et al.
Journal of the National Cancer Institute|March 8, 2012
CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trialMeredith M Regan, Brian Leyland-Jones, Mark Bouzyk, et al.
Genes & Development|May 29, 2025
NOTCH1 S2513 is critical for the regulation of NICD levels impacting the segmentation clock in hiPSC-derived PSM cells and somitoidsHedda A Meijer, Adam Hetherington, Sara J Johnson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2009
Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trialJi-Yeob Choi, William E Barlow, Kathy S Albain, et al.
Journal of Medicinal Chemistry|April 8, 2025
Correction to "Discovery of ERD-1233 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader for the Treatment of ER+ Human Breast Cancer"Ranjan Kumar Acharyya, Rohan Kalyan Rej, Biao Hu, et al.
Breast Cancer Research and Treatment|March 24, 2010
Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancerSong Yao, William E Barlow, Kathy S Albain, et al.
Journal of Medicinal Chemistry|November 1, 2024
Discovery of ERD-1233 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader for the Treatment of ER+ Human Breast CancerRanjan Kumar Acharyya, Rohan Kalyan Rej, Biao Hu, et al.
Pharmacogenomics|August 24, 2023
Effects of <i>CYP3A4</i> and <i>CYP2C9</i> genotype on systemic anastrozole and fulvestrant concentrations in SWOG S0226Delaney V Rutherford, Sarah Medley, Nicholas C Henderson, et al.
Pageof 30